Invivyd (NASDAQ:IVVD) Insider Robert Allen III Sells 19,392 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 19,392 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $30,639.36. Following the transaction, the insider directly owned 114,487 shares of the company’s stock, valued at approximately $180,889.46. This trade represents a 14.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Invivyd Stock Performance

IVVD opened at $1.65 on Thursday. The stock has a market capitalization of $384.65 million, a PE ratio of -3.51 and a beta of 0.60. The stock’s 50 day moving average price is $2.19 and its 200-day moving average price is $1.75. Invivyd, Inc. has a 52-week low of $0.46 and a 52-week high of $3.07.

More Invivyd News

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

Analyst Ratings Changes

Several brokerages recently issued reports on IVVD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. HC Wainwright boosted their target price on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Finally, Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Courier Capital LLC purchased a new position in shares of Invivyd in the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. purchased a new position in Invivyd during the fourth quarter valued at approximately $27,000. Catalyst Funds Management Pty Ltd bought a new position in Invivyd in the 2nd quarter worth $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd during the fourth quarter worth about $27,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after buying an additional 28,146 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.